Comparative Pharmacology
Head-to-head clinical analysis: CARTROL versus COREG CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTROL versus COREG CR.
CARTROL vs COREG CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Category C
Category C
Beta-Blocker
Beta-Blocker